Cargando…

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine

Naldemedine is a peripherally acting μ‐opioid‐receptor antagonist for the treatment of opioid‐induced constipation. Two phase 1 single‐dose studies investigated the pharmacokinetics and safety of a 0.2‐mg oral dose of naldemedine in subjects with renal impairment (mild, n = 9; moderate, n = 9; sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukumura, Kazuya, Yamada, Tadaaki, Yokota, Takaaki, Kawasaki, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027783/ https://www.ncbi.nlm.nih.gov/pubmed/30977959 http://dx.doi.org/10.1002/cpdd.690

Ejemplares similares

Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
por: Kubota, Ryuji, et al.
Publicado: (2018)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
por: Nafziger, Anne N., et al.
Publicado: (2019)

A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
por: Webster, Lynn R, et al.
Publicado: (2020)

Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives
por: Hale, Martin E., et al.
Publicado: (2021)

Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
por: Fukumura, Kazuya, et al.
Publicado: (2020)

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019)

Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
por: Wild, James, et al.
Publicado: (2020)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
por: Webster, Lynn R, et al.
Publicado: (2017)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Naldemedine: A New Option for OIBD
por: Coluzzi, Flaminia, et al.
Publicado: (2020)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)

Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
por: Trivedi, Ashit, et al.
Publicado: (2022)

Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials
por: Wild, James, et al.
Publicado: (2019)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
por: Mercier, Anne-Kristina, et al.
Publicado: (2023)

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
por: Kamiya, Teruhiko, et al.
Publicado: (2023)

Fentanyl/naldemedine: Diarrhoea and decreased peristalsis: case report
Publicado: (2021)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study
por: Webster, Lynn R., et al.
Publicado: (2018)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
por: Smolders, Elise J., et al.
Publicado: (2016)

Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
por: Takata, Keiko, et al.
Publicado: (2022)

Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018)

Influence of Brain Metastasis on Analgesia-Related Outcomes in Patients with Lung and Breast Cancers Treated with Naldemedine: A Propensity Score-Matched Analysis
por: Hanamoto, Aya, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
por: O’Donnell, John, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022)

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study
por: Nishiba, Hiromi, et al.
Publicado: (2022)

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vt6bh886o0i7it0r9fuf9ou5it